SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) announced that the phase
II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq and
chemotherapy versus pembrolizumab and chemotherapy as an initial treatment for
people with previously untreated, locally advanced unresectable or metastatic
non-squamous non-small cell lung cancer, did not meet its primary endpoints of
progression-free survival at its primary analysis with a hazard ratio of 1.27
and overall survival at its first interim analysis with a hazard ratio of 1.33,
which was immature. The company intends to halt the study due to reduced
efficacy compared to the comparator arm.

Based on the results, the company will evaluate any relevant changes needed to
the ongoing tiragolumab programme.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX